D
David Craufurd
Researcher at University of Manchester
Publications - 113
Citations - 12317
David Craufurd is an academic researcher from University of Manchester. The author has contributed to research in topics: Huntington's disease & Population. The author has an hindex of 44, co-authored 106 publications receiving 11254 citations. Previous affiliations of David Craufurd include Central Manchester University Hospitals NHS Foundation Trust & Manchester Academic Health Science Centre.
Papers
More filters
Journal ArticleDOI
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Mike Hutton,Corinne Lendon,Patrizia Rizzu,Matt Baker,Susanne Froelich,Susanne Froelich,Henry Houlden,Stuart Pickering-Brown,Sumitra Chakraverty,Adrian M. Isaacs,Andrew Grover,J. Hackett,Jennifer Adamson,Sarah Lincoln,Dennis W. Dickson,Peter Davies,Ronald C. Petersen,M. Stevens,E. De Graaff,E. Wauters,J. Van Baren,M. Hillebrand,Marijke Joosse,J. M. Kwon,Petra Nowotny,Lien Kuei Che,Joanne Norton,John C. Morris,L. A. Reed,John Q. Trojanowski,Hans Basun,Lars Lannfelt,M. Neystat,Stanley Fahn,Frances Dark,Tony Tannenberg,Peter R. Dodd,Nicholas K. Hayward,John B.J. Kwok,Peter R. Schofield,Athena Andreadis,Julie S. Snowden,David Craufurd,David Neary,F. Owen,Ben A. Oostra,John Hardy,Alison Goate,J. C. van Swieten,David M. A. Mann,Timothy Lynch,Peter Heutink +51 more
TL;DR: In this paper, the authors sequenced tau in FTDP-17 families and identified three missense mutations (G272V, P301L and R406W) and three mutations in the 5' splice site of exon in
Journal ArticleDOI
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.
Sarah J. Tabrizi,Douglas R. Langbehn,Blair R. Leavitt,Raymund A.C. Roos,Alexandra Durr,David Craufurd,Christopher Kennard,Stephen Hicks,Nick C. Fox,Rachael I. Scahill,Beth Borowsky,Allan J. Tobin,H. Diana Rosas,Hans J. Johnson,Ralf Reilmann,Bernhard Landwehrmeyer,Julie C. Stout,Julie C. Stout +17 more
TL;DR: The feasibility of rapid data acquisition and the use of multi-site 3T MRI and neurophysiological motor measures in a large multicentre study is shown, providing evidence for quantifiable biological and clinical alterations in HTT expansion carriers compared with age-matched controls.
Journal ArticleDOI
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data
Sarah J. Tabrizi,Rachael I. Scahill,Gail Owen,Alexandra Durr,Blair R. Leavitt,Raymund A.C. Roos,Beth Borowsky,Bernhard Landwehrmeyer,Chris Frost,Hans J. Johnson,David Craufurd,David Craufurd,R Reilmann,Julie C. Stout,Douglas R. Langbehn +14 more
TL;DR: In early HD, imaging, quantitative motor, and cognitive measures were predictive of decline in total functional capacity and tracked longitudinal change, and neuropsychiatric changes consistent with frontostriatal pathological abnormalities were associated with this loss of functional capacity.
Journal ArticleDOI
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis
Sarah J. Tabrizi,Rachael I. Scahill,Alexandra Durr,Raymund A.C. Roos,Blair R. Leavitt,Rebecca Jones,G. Bernhard Landwehrmeyer,Nick C. Fox,Hans J. Johnson,Stephen Hicks,Christopher Kennard,David Craufurd,Chris Frost,Douglas R. Langbehn,Ralf Reilmann,Julie C. Stout +15 more
TL;DR: The Track-HD study as discussed by the authors examined disease progression in premanifest individuals carrying the mutant HTT gene and those with early stage disease and reported 12-month longitudinal changes, building on baseline findings.
Journal ArticleDOI
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data
Sarah J. Tabrizi,R Reilmann,Raymond A. C. Roos,Alexandra Durr,Blair R. Leavitt,Gail Owen,Rebecca Jones,Hans J. Johnson,David Craufurd,Stephen Hicks,Christopher Kennard,Bernhard Landwehrmeyer,Julie C. Stout,Beth Borowsky,Rachael I. Scahill,Chris Frost,Douglas R. Langbehn +16 more
TL;DR: On the basis of longitudinal effect size, several objective outcome measures for clinical trials in participants with early HD are recommended and Hypothetical treatment effects defined by slower longitudinal changes in these measures would be detectable over a realistic timescale with practical sample sizes.